1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CNS Oral Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for CNS Oral Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for CNS Oral Drugs by Country/Region, 2018, 2022 & 2029
2.2 CNS Oral Drugs Segment by Type
2.2.1 Antidepressants
2.2.2 Antipsychotics
2.2.3 Anti-Dementia Drugs
2.2.4 Anti-Parkinson’s Drugs
2.2.5 Antiepileptic Drugs
2.2.6 Others
2.3 CNS Oral Drugs Sales by Type
2.3.1 Global CNS Oral Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global CNS Oral Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global CNS Oral Drugs Sale Price by Type (2018-2023)
2.4 CNS Oral Drugs Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Pharmacy
2.5 CNS Oral Drugs Sales by Application
2.5.1 Global CNS Oral Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global CNS Oral Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global CNS Oral Drugs Sale Price by Application (2018-2023)
3 Global CNS Oral Drugs by Company
3.1 Global CNS Oral Drugs Breakdown Data by Company
3.1.1 Global CNS Oral Drugs Annual Sales by Company (2018-2023)
3.1.2 Global CNS Oral Drugs Sales Market Share by Company (2018-2023)
3.2 Global CNS Oral Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global CNS Oral Drugs Revenue by Company (2018-2023)
3.2.2 Global CNS Oral Drugs Revenue Market Share by Company (2018-2023)
3.3 Global CNS Oral Drugs Sale Price by Company
3.4 Key Manufacturers CNS Oral Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CNS Oral Drugs Product Location Distribution
3.4.2 Players CNS Oral Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for CNS Oral Drugs by Geographic Region
4.1 World Historic CNS Oral Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global CNS Oral Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global CNS Oral Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic CNS Oral Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global CNS Oral Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global CNS Oral Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas CNS Oral Drugs Sales Growth
4.4 APAC CNS Oral Drugs Sales Growth
4.5 Europe CNS Oral Drugs Sales Growth
4.6 Middle East & Africa CNS Oral Drugs Sales Growth
5 Americas
5.1 Americas CNS Oral Drugs Sales by Country
5.1.1 Americas CNS Oral Drugs Sales by Country (2018-2023)
5.1.2 Americas CNS Oral Drugs Revenue by Country (2018-2023)
5.2 Americas CNS Oral Drugs Sales by Type
5.3 Americas CNS Oral Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CNS Oral Drugs Sales by Region
6.1.1 APAC CNS Oral Drugs Sales by Region (2018-2023)
6.1.2 APAC CNS Oral Drugs Revenue by Region (2018-2023)
6.2 APAC CNS Oral Drugs Sales by Type
6.3 APAC CNS Oral Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CNS Oral Drugs by Country
7.1.1 Europe CNS Oral Drugs Sales by Country (2018-2023)
7.1.2 Europe CNS Oral Drugs Revenue by Country (2018-2023)
7.2 Europe CNS Oral Drugs Sales by Type
7.3 Europe CNS Oral Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CNS Oral Drugs by Country
8.1.1 Middle East & Africa CNS Oral Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa CNS Oral Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa CNS Oral Drugs Sales by Type
8.3 Middle East & Africa CNS Oral Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CNS Oral Drugs
10.3 Manufacturing Process Analysis of CNS Oral Drugs
10.4 Industry Chain Structure of CNS Oral Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CNS Oral Drugs Distributors
11.3 CNS Oral Drugs Customer
12 World Forecast Review for CNS Oral Drugs by Geographic Region
12.1 Global CNS Oral Drugs Market Size Forecast by Region
12.1.1 Global CNS Oral Drugs Forecast by Region (2024-2029)
12.1.2 Global CNS Oral Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CNS Oral Drugs Forecast by Type
12.7 Global CNS Oral Drugs Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer CNS Oral Drugs Product Portfolios and Specifications
13.1.3 Pfizer CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Biogen
13.2.1 Biogen Company Information
13.2.2 Biogen CNS Oral Drugs Product Portfolios and Specifications
13.2.3 Biogen CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Biogen Main Business Overview
13.2.5 Biogen Latest Developments
13.3 Otsuka
13.3.1 Otsuka Company Information
13.3.2 Otsuka CNS Oral Drugs Product Portfolios and Specifications
13.3.3 Otsuka CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Otsuka Main Business Overview
13.3.5 Otsuka Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis CNS Oral Drugs Product Portfolios and Specifications
13.4.3 Novartis CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Teva Pharmaceutical
13.5.1 Teva Pharmaceutical Company Information
13.5.2 Teva Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
13.5.3 Teva Pharmaceutical CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Teva Pharmaceutical Main Business Overview
13.5.5 Teva Pharmaceutical Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson CNS Oral Drugs Product Portfolios and Specifications
13.6.3 Johnson & Johnson CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 AstraZeneca
13.7.1 AstraZeneca Company Information
13.7.2 AstraZeneca CNS Oral Drugs Product Portfolios and Specifications
13.7.3 AstraZeneca CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 AstraZeneca Main Business Overview
13.7.5 AstraZeneca Latest Developments
13.8 Merck
13.8.1 Merck Company Information
13.8.2 Merck CNS Oral Drugs Product Portfolios and Specifications
13.8.3 Merck CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Merck Main Business Overview
13.8.5 Merck Latest Developments
13.9 GSK
13.9.1 GSK Company Information
13.9.2 GSK CNS Oral Drugs Product Portfolios and Specifications
13.9.3 GSK CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 GSK Main Business Overview
13.9.5 GSK Latest Developments
13.10 Eli Lilly and Company
13.10.1 Eli Lilly and Company Company Information
13.10.2 Eli Lilly and Company CNS Oral Drugs Product Portfolios and Specifications
13.10.3 Eli Lilly and Company CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Eli Lilly and Company Main Business Overview
13.10.5 Eli Lilly and Company Latest Developments
13.11 Lundbeck
13.11.1 Lundbeck Company Information
13.11.2 Lundbeck CNS Oral Drugs Product Portfolios and Specifications
13.11.3 Lundbeck CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Lundbeck Main Business Overview
13.11.5 Lundbeck Latest Developments
13.12 Takeda
13.12.1 Takeda Company Information
13.12.2 Takeda CNS Oral Drugs Product Portfolios and Specifications
13.12.3 Takeda CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Takeda Main Business Overview
13.12.5 Takeda Latest Developments
13.13 Bristol Myers Squibb
13.13.1 Bristol Myers Squibb Company Information
13.13.2 Bristol Myers Squibb CNS Oral Drugs Product Portfolios and Specifications
13.13.3 Bristol Myers Squibb CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Bristol Myers Squibb Main Business Overview
13.13.5 Bristol Myers Squibb Latest Developments
13.14 Jiangsu Nhwa Pharmaceutical
13.14.1 Jiangsu Nhwa Pharmaceutical Company Information
13.14.2 Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
13.14.3 Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Jiangsu Nhwa Pharmaceutical Main Business Overview
13.14.5 Jiangsu Nhwa Pharmaceutical Latest Developments
13.15 Luye Pharma
13.15.1 Luye Pharma Company Information
13.15.2 Luye Pharma CNS Oral Drugs Product Portfolios and Specifications
13.15.3 Luye Pharma CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Luye Pharma Main Business Overview
13.15.5 Luye Pharma Latest Developments
13.16 Zhejiang Huahai Pharmaceutical
13.16.1 Zhejiang Huahai Pharmaceutical Company Information
13.16.2 Zhejiang Huahai Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
13.16.3 Zhejiang Huahai Pharmaceutical CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Zhejiang Huahai Pharmaceutical Main Business Overview
13.16.5 Zhejiang Huahai Pharmaceutical Latest Developments
13.17 Chengdu Easton Biopharmaceuticals
13.17.1 Chengdu Easton Biopharmaceuticals Company Information
13.17.2 Chengdu Easton Biopharmaceuticals CNS Oral Drugs Product Portfolios and Specifications
13.17.3 Chengdu Easton Biopharmaceuticals CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Chengdu Easton Biopharmaceuticals Main Business Overview
13.17.5 Chengdu Easton Biopharmaceuticals Latest Developments
13.18 Hansoh Pharmaceutical
13.18.1 Hansoh Pharmaceutical Company Information
13.18.2 Hansoh Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
13.18.3 Hansoh Pharmaceutical CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Hansoh Pharmaceutical Main Business Overview
13.18.5 Hansoh Pharmaceutical Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. CNS Oral Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. CNS Oral Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Antidepressants
Table 4. Major Players of Antipsychotics
Table 5. Major Players of Anti-Dementia Drugs
Table 6. Major Players of Anti-Parkinson's Drugs
Table 7. Major Players of Antiepileptic Drugs
Table 8. Major Players of Others
Table 9. Global CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 10. Global CNS Oral Drugs Sales Market Share by Type (2018-2023)
Table 11. Global CNS Oral Drugs Revenue by Type (2018-2023) & ($ million)
Table 12. Global CNS Oral Drugs Revenue Market Share by Type (2018-2023)
Table 13. Global CNS Oral Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 14. Global CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 15. Global CNS Oral Drugs Sales Market Share by Application (2018-2023)
Table 16. Global CNS Oral Drugs Revenue by Application (2018-2023)
Table 17. Global CNS Oral Drugs Revenue Market Share by Application (2018-2023)
Table 18. Global CNS Oral Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 19. Global CNS Oral Drugs Sales by Company (2018-2023) & (K Units)
Table 20. Global CNS Oral Drugs Sales Market Share by Company (2018-2023)
Table 21. Global CNS Oral Drugs Revenue by Company (2018-2023) ($ Millions)
Table 22. Global CNS Oral Drugs Revenue Market Share by Company (2018-2023)
Table 23. Global CNS Oral Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 24. Key Manufacturers CNS Oral Drugs Producing Area Distribution and Sales Area
Table 25. Players CNS Oral Drugs Products Offered
Table 26. CNS Oral Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global CNS Oral Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 30. Global CNS Oral Drugs Sales Market Share Geographic Region (2018-2023)
Table 31. Global CNS Oral Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 32. Global CNS Oral Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 33. Global CNS Oral Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 34. Global CNS Oral Drugs Sales Market Share by Country/Region (2018-2023)
Table 35. Global CNS Oral Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 36. Global CNS Oral Drugs Revenue Market Share by Country/Region (2018-2023)
Table 37. Americas CNS Oral Drugs Sales by Country (2018-2023) & (K Units)
Table 38. Americas CNS Oral Drugs Sales Market Share by Country (2018-2023)
Table 39. Americas CNS Oral Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 40. Americas CNS Oral Drugs Revenue Market Share by Country (2018-2023)
Table 41. Americas CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 42. Americas CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 43. APAC CNS Oral Drugs Sales by Region (2018-2023) & (K Units)
Table 44. APAC CNS Oral Drugs Sales Market Share by Region (2018-2023)
Table 45. APAC CNS Oral Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 46. APAC CNS Oral Drugs Revenue Market Share by Region (2018-2023)
Table 47. APAC CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 48. APAC CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 49. Europe CNS Oral Drugs Sales by Country (2018-2023) & (K Units)
Table 50. Europe CNS Oral Drugs Sales Market Share by Country (2018-2023)
Table 51. Europe CNS Oral Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 52. Europe CNS Oral Drugs Revenue Market Share by Country (2018-2023)
Table 53. Europe CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 54. Europe CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 55. Middle East & Africa CNS Oral Drugs Sales by Country (2018-2023) & (K Units)
Table 56. Middle East & Africa CNS Oral Drugs Sales Market Share by Country (2018-2023)
Table 57. Middle East & Africa CNS Oral Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 58. Middle East & Africa CNS Oral Drugs Revenue Market Share by Country (2018-2023)
Table 59. Middle East & Africa CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 60. Middle East & Africa CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of CNS Oral Drugs
Table 62. Key Market Challenges & Risks of CNS Oral Drugs
Table 63. Key Industry Trends of CNS Oral Drugs
Table 64. CNS Oral Drugs Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. CNS Oral Drugs Distributors List
Table 67. CNS Oral Drugs Customer List
Table 68. Global CNS Oral Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. Global CNS Oral Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Americas CNS Oral Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Americas CNS Oral Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. APAC CNS Oral Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 73. APAC CNS Oral Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Europe CNS Oral Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Europe CNS Oral Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Middle East & Africa CNS Oral Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Middle East & Africa CNS Oral Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Global CNS Oral Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 79. Global CNS Oral Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 80. Global CNS Oral Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 81. Global CNS Oral Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 82. Pfizer Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer CNS Oral Drugs Product Portfolios and Specifications
Table 84. Pfizer CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. Biogen Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Biogen CNS Oral Drugs Product Portfolios and Specifications
Table 89. Biogen CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Biogen Main Business
Table 91. Biogen Latest Developments
Table 92. Otsuka Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Otsuka CNS Oral Drugs Product Portfolios and Specifications
Table 94. Otsuka CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Otsuka Main Business
Table 96. Otsuka Latest Developments
Table 97. Novartis Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Novartis CNS Oral Drugs Product Portfolios and Specifications
Table 99. Novartis CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Novartis Main Business
Table 101. Novartis Latest Developments
Table 102. Teva Pharmaceutical Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Teva Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
Table 104. Teva Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Teva Pharmaceutical Main Business
Table 106. Teva Pharmaceutical Latest Developments
Table 107. Johnson & Johnson Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Johnson & Johnson CNS Oral Drugs Product Portfolios and Specifications
Table 109. Johnson & Johnson CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Johnson & Johnson Main Business
Table 111. Johnson & Johnson Latest Developments
Table 112. AstraZeneca Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. AstraZeneca CNS Oral Drugs Product Portfolios and Specifications
Table 114. AstraZeneca CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. AstraZeneca Main Business
Table 116. AstraZeneca Latest Developments
Table 117. Merck Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Merck CNS Oral Drugs Product Portfolios and Specifications
Table 119. Merck CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Merck Main Business
Table 121. Merck Latest Developments
Table 122. GSK Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. GSK CNS Oral Drugs Product Portfolios and Specifications
Table 124. GSK CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. GSK Main Business
Table 126. GSK Latest Developments
Table 127. Eli Lilly and Company Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Eli Lilly and Company CNS Oral Drugs Product Portfolios and Specifications
Table 129. Eli Lilly and Company CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Eli Lilly and Company Main Business
Table 131. Eli Lilly and Company Latest Developments
Table 132. Lundbeck Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. Lundbeck CNS Oral Drugs Product Portfolios and Specifications
Table 134. Lundbeck CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. Lundbeck Main Business
Table 136. Lundbeck Latest Developments
Table 137. Takeda Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Takeda CNS Oral Drugs Product Portfolios and Specifications
Table 139. Takeda CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. Takeda Main Business
Table 141. Takeda Latest Developments
Table 142. Bristol Myers Squibb Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 143. Bristol Myers Squibb CNS Oral Drugs Product Portfolios and Specifications
Table 144. Bristol Myers Squibb CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 145. Bristol Myers Squibb Main Business
Table 146. Bristol Myers Squibb Latest Developments
Table 147. Jiangsu Nhwa Pharmaceutical Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 148. Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
Table 149. Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 150. Jiangsu Nhwa Pharmaceutical Main Business
Table 151. Jiangsu Nhwa Pharmaceutical Latest Developments
Table 152. Luye Pharma Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 153. Luye Pharma CNS Oral Drugs Product Portfolios and Specifications
Table 154. Luye Pharma CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 155. Luye Pharma Main Business
Table 156. Luye Pharma Latest Developments
Table 157. Zhejiang Huahai Pharmaceutical Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 158. Zhejiang Huahai Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
Table 159. Zhejiang Huahai Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 160. Zhejiang Huahai Pharmaceutical Main Business
Table 161. Zhejiang Huahai Pharmaceutical Latest Developments
Table 162. Chengdu Easton Biopharmaceuticals Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 163. Chengdu Easton Biopharmaceuticals CNS Oral Drugs Product Portfolios and Specifications
Table 164. Chengdu Easton Biopharmaceuticals CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 165. Chengdu Easton Biopharmaceuticals Main Business
Table 166. Chengdu Easton Biopharmaceuticals Latest Developments
Table 167. Hansoh Pharmaceutical Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 168. Hansoh Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
Table 169. Hansoh Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 170. Hansoh Pharmaceutical Main Business
Table 171. Hansoh Pharmaceutical Latest Developments
List of Figures
Figure 1. Picture of CNS Oral Drugs
Figure 2. CNS Oral Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global CNS Oral Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global CNS Oral Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. CNS Oral Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Antidepressants
Figure 10. Product Picture of Antipsychotics
Figure 11. Product Picture of Anti-Dementia Drugs
Figure 12. Product Picture of Anti-Parkinson's Drugs
Figure 13. Product Picture of Antiepileptic Drugs
Figure 14. Product Picture of Others
Figure 15. Global CNS Oral Drugs Sales Market Share by Type in 2022
Figure 16. Global CNS Oral Drugs Revenue Market Share by Type (2018-2023)
Figure 17. CNS Oral Drugs Consumed in Hospital and Clinic
Figure 18. Global CNS Oral Drugs Market: Hospital and Clinic (2018-2023) & (K Units)
Figure 19. CNS Oral Drugs Consumed in Pharmacy
Figure 20. Global CNS Oral Drugs Market: Pharmacy (2018-2023) & (K Units)
Figure 21. Global CNS Oral Drugs Sales Market Share by Application (2022)
Figure 22. Global CNS Oral Drugs Revenue Market Share by Application in 2022
Figure 23. CNS Oral Drugs Sales Market by Company in 2022 (K Units)
Figure 24. Global CNS Oral Drugs Sales Market Share by Company in 2022
Figure 25. CNS Oral Drugs Revenue Market by Company in 2022 ($ Million)
Figure 26. Global CNS Oral Drugs Revenue Market Share by Company in 2022
Figure 27. Global CNS Oral Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global CNS Oral Drugs Revenue Market Share by Geographic Region in 2022
Figure 29. Americas CNS Oral Drugs Sales 2018-2023 (K Units)
Figure 30. Americas CNS Oral Drugs Revenue 2018-2023 ($ Millions)
Figure 31. APAC CNS Oral Drugs Sales 2018-2023 (K Units)
Figure 32. APAC CNS Oral Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Europe CNS Oral Drugs Sales 2018-2023 (K Units)
Figure 34. Europe CNS Oral Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa CNS Oral Drugs Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa CNS Oral Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Americas CNS Oral Drugs Sales Market Share by Country in 2022
Figure 38. Americas CNS Oral Drugs Revenue Market Share by Country in 2022
Figure 39. Americas CNS Oral Drugs Sales Market Share by Type (2018-2023)
Figure 40. Americas CNS Oral Drugs Sales Market Share by Application (2018-2023)
Figure 41. United States CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC CNS Oral Drugs Sales Market Share by Region in 2022
Figure 46. APAC CNS Oral Drugs Revenue Market Share by Regions in 2022
Figure 47. APAC CNS Oral Drugs Sales Market Share by Type (2018-2023)
Figure 48. APAC CNS Oral Drugs Sales Market Share by Application (2018-2023)
Figure 49. China CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. India CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe CNS Oral Drugs Sales Market Share by Country in 2022
Figure 57. Europe CNS Oral Drugs Revenue Market Share by Country in 2022
Figure 58. Europe CNS Oral Drugs Sales Market Share by Type (2018-2023)
Figure 59. Europe CNS Oral Drugs Sales Market Share by Application (2018-2023)
Figure 60. Germany CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. France CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa CNS Oral Drugs Sales Market Share by Country in 2022
Figure 66. Middle East & Africa CNS Oral Drugs Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa CNS Oral Drugs Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa CNS Oral Drugs Sales Market Share by Application (2018-2023)
Figure 69. Egypt CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of CNS Oral Drugs in 2022
Figure 75. Manufacturing Process Analysis of CNS Oral Drugs
Figure 76. Industry Chain Structure of CNS Oral Drugs
Figure 77. Channels of Distribution
Figure 78. Global CNS Oral Drugs Sales Market Forecast by Region (2024-2029)
Figure 79. Global CNS Oral Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global CNS Oral Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global CNS Oral Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global CNS Oral Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global CNS Oral Drugs Revenue Market Share Forecast by Application (2024-2029)

※参考情報 中枢神経系経口薬（CNS Oral Drugs）は、脳や脊髄などの中枢神経系に作用するために設計された経口投与型の医薬品です。これらの薬剤は、さまざまな神経系の疾患や障害に対処するために使用され、患者の生活の質を向上させることを目的としています。中枢神経系に関連する疾患には、うつ病、統合失調症、てんかん、不安障害、アルツハイマー病、パーキンソン病などがあります。 経口薬は、その名の通り口から摂取され、消化器系を介して体内に吸収され、全身循環に入ります。多くの場合、経口投与は注射や点滴に比べて患者にとって手軽であり、自己管理がしやすいという利点があります。 中枢神経系経口薬は、いくつかの特徴があります。まず、これらの薬剤は脳血液関門（blood-brain barrier）を透過する能力が求められます。この関門は、脳を保護する役割を果たしており、脳内への不要な物質の侵入を防いでいます。そのため、中枢神経系治療薬は血液脳関門を越える特性を持つことが重要です。 また、経口薬は一般的に副作用が少なく、投与の容易さから患者のコンプライアンスも高まる傾向にあります。しかし、一方で、効果が現れるまでに時間がかかることや、吸収率に個人差があること、食事の影響を受けることなどの課題も存在します。これは、特に神経系の疾患では、投与後の効果をすぐに評価しづらいケースが多いことを意味します。 種類としては、抗うつ薬、抗精神病薬、抗てんかん薬、抗不安薬、認知症治療薬などが含まれます。抗うつ薬には、選択的セロトニン再取り込み阻害薬（SSRI）や三環系抗うつ薬（TCA）などがあり、うつ症状の軽減を目的としています。抗精神病薬は、統合失調症や双極性障害の管理に使用されることが多く、第一世代および第二世代の薬剤が存在します。 抗てんかん薬は、発作を抑える目的で広く使用されており、カーボマゼピンやバルプロ酸ナトリウムなどが代表的です。抗不安薬には、ベンゾジアゼピン系薬物が一般的で、短期間の不安緩和に利用されます。認知症治療薬としては、アセチルコリンエステラーゼ阻害薬が多く使われており、アルツハイマー病患者の認知機能を改善する効果が期待されます。 これらの中枢神経系経口薬は、さまざまな用途に応じて処方されます。例えば、抗うつ薬はうつ病や不安障害の治療に使用され、精神病治療は統合失調症や双極性障害において重要です。また、てんかんや神経痛の管理には抗てんかん薬が選ばれます。さらに、認知症の進行を遅らせるための治療として、認知症治療薬が用いられます。 関連技術としては、薬物の効果を高めるためのドラッグデリバリーシステム（DDS）が挙げられます。DDSは、薬物を効果的に目的の部位に届けるための技術で、ナノテクノロジーやマイクロエンキャプスレーション技術などが活用されています。これにより、薬物の安定性や生体内での放出特性を向上させ、治療効果を高めることが可能になります。 このように中枢神経系経口薬は、神経系の疾患や障害に対する治療の中心的な役割を担っており、多くの患者にとって欠かせない治療手段となっています。経口薬の利点は、その使用の容易さと患者のアクセシビリティの向上に寄与しています。一方で、依然として新たな薬剤の開発や既存薬のメカニズムの解明が求められており、より効果的な治療法の確立が望まれています。今後の研究と開発により、より多くの中枢神経系疾患への対応が期待されており、技術の進歩と共に新たな治療選択肢が提供されることが重要です。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer